Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Liver Involvement in Celiac Disease
Minerva Med 99:595-604, Rubio-Tapia,A. & Murray,J.A., 2008
Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008
Response of Anti-NMDA Receptor Encephalitis Without Tumor to Immunotherapy Including Rituximab
Neurol 71:1921-1923, Ishiura,H.,et al, 2008
Treatment of Neuromyelitis Optica with Rituximab; Retrospective Analysis of 25 Patients
Arch Neurol 65:1443-1448, Jacob,A.,et al, 2008
Plasma Exchange for Anti GAD Associated Non Paraneoplastic Limbic Encephalitis
Transfus Apher Sci 39:229-233, Mazzi,G.,et al, 2008
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Lymphomatoid Granulomatosis Involving Central Nervous System Successfully Treated With Rituximab alone
Arch Neurol 65:662-665, Ishiura,H.,et al, 2008
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy
Mod Rheumatol 18:399-402, Kameda, T.,et al, 2008
Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis
Mod Rheumatol 17-72-74, Yamamoto, M.,et al, 2007
Intracranial Hemorrhage in Patients Treated with Bevacizumab and Low-Molecular Weight Heparin
Clin Adv Hematol Oncol 5:375-379, Nguyen, T.D.,et al, 2007
Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007
Refractory Neurosarcoidosis Responsive to Infliximab
Pract Neurol 7:112-115, Kobylecki,C. &Shaunak,S., 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Neuralgic Amyotrophy, Diagnosed With Magnetic Resonance Neurography in Acute Stage: A Case Report and Review of the Literature
The Neurologist 13:219-221, Duman,I.,et al, 2007
Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007
Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Neurologist 13:261-271, Tuzun,E. &Dalmau,J., 2007
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Vascultic Neuropathies: An Update
The Neurologist 13:12-19, Gorson,K.C., 2007
Occult Celiac Disease Presenting as Epilepsy and MRI Changes That Responded to Gluten-Free Diet
Neurol 68:533-534, Harper,E.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Rapidly Fatal Acanthamoeba Encephalitis and Treatment of Cryoglobulinemia
Emerg Infect Dis 13:469-471, Meersseman, W.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006
Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Phrenic Neuropathy Due to Neuralgic Amyotrophy
Neurol 66:1582-1584, Tsao,B.E.,et al, 2006
Multifocal Axonal Polyneuropathy in Celiac Disease
Neurol 66:1923-1925, Chin,R.L.,et al, 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Progressive Multifocal Leukoencephalopathy Revisited: Has the Disease Outgrown Its Name?
Ann Neurol 60:162-173, Koralnik,I.J., 2006
Diagnosis of Neurolymphomatosis with FDG PET
Neurol 67:722-723, Rosso,S.M.,et al, 2006
Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006
The Clinical Spectrum of Neuralgic Amyotrophy in 246 cases
Brain 129:438-450, Alfen, N.V. & Baziel, G.M., 2006
Radiculoplexopathy with Conduction Block Caused by Acute Epstein-Barr Virus Infection
Neurol 64:530-532, Vucic, S., et al, 2005
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Autoantibodies to Folate Receptors in the Cerebral Folate Deficiency Syndrome
NEJM 352:1985-1991, Ramaekers,V.T.,et al, 2005
A Floppy Child with Failure to Thrive
Lancet 366:176, Loma-Sanner,I.,et al, 2005
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Efficacy of TNF a Blockade in Cyclophosphamide Resistant Neuro-Behet Disease
JNNP 76:1733-1735, Ribi,C.,et al, 2005